It’s not about age, but about stage.
At miRoncol, we believe that prevention begins with awareness — not just of family history or genetic predisposition, but of what’s happening inside the body right now. Our mission is to make real-time cancer risk assessment a standard part of preventive care, empowering individuals and healthcare providers with meaningful molecular insight.
Why We Exist
- Cancer touches 1 in 3 people in their lifetime, yet more than 4 in 5 cancers are missed by current screening programs.
- Screening is essential, but it is limited to certain cancers, age groups, and eligibility criteria.
- We exist to close this gap by providing real-time molecular information that complements physician-led diagnostics and existing programs.
What We Do
miRoncol delivers the Real-time Multi-Cancer Early Risk Assessment a blood-based test that:
- Detects microRNA biomarkers, sensitive signals of early cellular change
- Uses AI-enhanced recognition trained from studies using human data involving 11,000+ samples
- Covers more than a dozen common solid tumours
- Provides specificity above 99% with high sensitivity for many cancers
How We Do It
- Prevention-first mindset: empowering individuals before symptoms appear
- Collaboration with healthcare providers: results are designed to be interpreted with physicians
- Ethical communication: ensuring results are shared responsibly, without overpromising
- Scientific transparency: peer-reviewed publications, validated performance, and based on Nobel-recognized science
Our Vision
We envision a future where:
- Real-time molecular testing is as routine as annual checkup
- Prevention and early detection is prioritized alongside treatment
- Millions of lives are saved through earlier awareness and follow-up
Next Step
Join us in shaping a prevention-forward future, where meaningful insight leads to more informed choices and healthier lives.
